Taken together, our study identifies a pro‐senescence axis, TBK1‐ATAD3A‐Pink1, and provides a potential clinical target for anti‐aging therapies and strategies to combat chemoresistance in tumor treatments. This evidence concerns the gene ATAD3A and neoplasm.